I Squared Capital Appoints Gautam Bhandari as Global Chief Investment Officer
19.5.2023 15:00:00 EEST | Business Wire | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that Gautam Bhandari, co-founder and Managing Partner, has been appointed as I Squared Capital’s Global Chief Investment Officer, responsible for leading the firm’s global investment strategy in close collaboration with founder, Chairman and Managing Partner Sadek Wahba. This new appointment is part of additional changes to its management and governance structure that will build on the firm’s success to further institutionalize I Squared Capital for the coming decade and beyond.
In addition, I Squared Capital has named Mohamed Adel El-Gazzar and Harsh Agrawal as Senior Partners and members of the Executive Committee of the firm. The newly formed Executive Committee will lead the strategic development of the firm.
“These structural enhancements come at an important moment for I Squared,” said Dr. Wahba. “As we reflect on the tremendous success of the past decade, we are taking steps to further institutionalize our firm and ensure that we are well positioned to capitalize on the unique opportunities of the next decade and beyond.”
“As I Squared continues to grow, I look forward to working with the Executive Committee to ensure that new fundraises and investments are calibrated to the firm’s disciplined approach of investing in and building high-quality, world-class businesses for the future,” said Dr. Bhandari. “We believe the demand for infrastructure will continue to grow globally as many capital-intensive sectors of the economy, such as energy, telecommunications, and transportation urgently need to modernize and also address the ever-increasing demand for sustainable infrastructure.”
Dr. Bhandari, co-founder and Managing Partner, has been a member of the Investment Committees of I Squared Capital since inception and he chairs the boards of several I Squared Capital portfolio companies globally. Prior to I Squared Capital, he was a Managing Director at Morgan Stanley where, for over ten years, he worked on infrastructure investments, as well as banking and capital markets. He holds a Ph.D. in Chemistry from the University of Delaware, where he was the University Merit Fellow and recipient of the Joel L. Silver Award for the best doctoral dissertation work, and an MBA in Finance from the Stern School of Business at New York University, where he was an Amerada Hess Merit Scholar.
Furthermore, I Squared Capital has formed an Operating Committee to manage the operations of the firm and to support the continued global growth of the platform. The Operating Committee will consist of the firm’s Partners along with a broader group of senior executives of I Squared Capital. The global platform has grown to over 215 employees, having hired 81 professionals since the start of 2022.
In parallel, Adil Rahmathulla, Managing Partner, will be transitioning from his role at I Squared Capital over the coming year to pursue other opportunities. He will remain on the firm’s Investment Committees ahead of his eventual departure from the firm in June 2024.
Dr. Wahba and Dr. Bhandari stated, “We are extremely grateful to Adil for the vital role he has played in co-founding and growing I Squared Capital. He has been a great partner, and we are pleased he will continue to work closely with us over the coming year. We are confident he will be successful in his future endeavors, and we wish him all the best.”
“It has been a privilege to work alongside Sadek, Gautam and the I Squared Capital team to contribute to the firm’s growth into one of the world’s leading infrastructure investors,” said Mr. Rahmathulla. “I am immensely proud of what we have achieved over the last decade and am excited to watch and support the firm’s continued success. I am grateful to Sadek and Gautam for their partnership and friendship, and I look forward to continuing my journey as an investor and entrepreneur in the years ahead.”
As part of these changes, over twenty senior employees of the firm, in addition to the existing shareholders, will be investing their own capital into the equity ownership of I Squared Capital, further broadening the firm’s shareholder base and strengthening alignment of interests. No financial details will be disclosed.
About I Squared Capital
I Squared Capital is an independent global infrastructure manager with over $37 billion in assets under management focused on investing in North America, Europe, Asia, and Latin America. Headquartered in Miami, the firm has more than 215 professionals across its offices in Miami, Hong Kong, London, New Delhi, Singapore, Taipei, and Sydney. I Squared Capital has invested in a diverse portfolio of 77 companies in 59 countries with over 31,000 employees across the utilities, energy, digital infrastructure, transport, environmental infrastructure, and social infrastructure sectors providing essential services to millions of people around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230519005039/en/
Contact information
Media Contacts
Brunswick Group
Alex Yankus / Clare Pickett
+1 (917) 818-5204 / +1 (347) 477 7475
isquared@brunswickgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 23:30:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
